BRD4 and ovarian carcinoma: The observation that BRD4 ablation is detrimental to OVSAHO cell growth is in agreement with CRISPR-Cas9 dependency data from the Dependency Map Consortium (DepMap Public 23Q4 release, http://depmap.org), where BRD4 scores as a genetic dependency (mean Chronos score = −0.99 ± 0.28) and is essential in 33/59 (∼56%) of ovarian cancer cell lines (Figure 4G).